Introduction
Gastrointestinal malignancies remain among the most common causes of cancer death world-wide and surgical resection is the only therapeutic modality capable of cure. 5-Fluorouracil (5-FU) is the most active single agent in gastric and colorectal cancers with response rates of approximately 30% and 20%, respectively. Interest in infusional chemotherapy increased following a randomized trial in advanced colorectal cancer comparing bolus to infusional 5-FU demonstrated higher response rates with less toxicity in patients treated with infusional 5-FU. The Royal Marsden Hospital gastrointestinal unit has developed an ambulatory chemotherapy service. The studies have demonstrated that protracted venous infusion (PVI 5-FU) has high activity with low toxicity. In gastric cancer, the combination with epirubicin and cisplatin, the ECF regimen, has demonstrated a higher response rate and survival advantage compared to 5-FU, methotrexate and adriamycin. ECF has demonstrated a 40% response rate with one-year survival of 42% in hepatobiliary cancer whilst CF is effective in pancreatic cancer. In colorectal cancer PVI 5-FU achieved a response rate of 28% with oneyear survival of 45%. The toxicity of PVI 5-FU is significantly less than the toxicity of folinic acid modulated bolus 5-FU. Tunnelled central venous catheters have been inserted in 832 patients with only 18% of catheters requiring removal for complications and minimal impact on quality of life. Hospital-based cost analyses have demonstrated that ambulatory chemotherapy is cost-effective.
The cytotoxic activity of antimetabolite agents such as 5-fluorouracil (5-FU) is during the S phase of the cell cycle. However, 5-FU has a short plasma half life, approximately 11 minutes, and uptake of 5-FU is seen in only 3% of human colon cancer cells. Thus, only a small proportion of tumour cells are susceptible to each bolus dose. 5-FU acts via a cytotoxic metabolite fluorodeoxyuridine monophosphate (FdUMP) which binds to thymidylate synthase (TS). Folinic acid stabilises the complex formed between FdUMP and TS prolonging the duration of binding and increasing efficacy. However, FA-modulated 5-FU regimens may result in serious toxicity and toxic deaths have been observed. Infusional regimens increase the number of cells exposed to 5-FU whilst in the S phase of the cell cycle and are an alternative strategy for enhancing the efficacy of 5-FU. In metastatic colorectal cancer PVI 5-FU resulted in higher response rates than unmodulated bolus 5-FU regimens with less toxicity, although survival was not improved [1] . Short infusions (1-2 day) and PVI 5-FU have been demonstrated to ameliorate the toxicity of FA-modulated 5-FU [2, 3] . The higher response rates and improved toxicity profile of PVI 5-FU was the rationale for the Royal Marsden Hospital gastrointestinal unit studies in oesophagogastric, hepatobiliary, pancreatic and colorectal cancers.
Oesophagogastric cancer
Oesophagogastric adenocarcinoma remains the most frequent cause of cancer deaths world-wide, despite a declining incidence in developed nations [4] . The prognosis remains poor, with 10%-15% five-year survival, due to frequent local and distant relapse, even after a complete resection, and because many patients have advanced disease at diagnosis [5] [6] . The drugs were chosen on the basis of their single agent activity in upper GI cancer, and the potential synergy between 5-FU and cisplatin. An anthracycline was included because of anticipated enhanced cytotoxicity afforded by its use in combination with the other two drugs. The phase II study included 235 patients with a median follow-up of eight months. An overall objective response rate of 61% was observed including 11% complete responses. The response rate in locally advanced disease was 75% with 24% achieving a complete response, and six patients having pathological complete response in resected specimens [7] . The results of a multicentre randomized study comparing ECF with FAMTX in 274 patients have demonstrated a higher response rate (45% vs. 21%; P = 0.0002) and improved median overall and failure-free survival (8.9 vs. 5.7 months, P = 0.0009 and 7.4 vs. 3.4 months, P = 0.00006, respectively). FAMTX caused more serious haematological toxcity and serious infection whilst ECF resulted in more vomiting and mucositis. Global quality of life scores were higher for ECF at 24 weeks [8] . Based on this evidence we would recommend that ECF should be regarded as the standard chemotherapy treatment for oesophagogastric cancer.
The role of adjuvant chemotherapy for gastric cancer is unproven but these results emphasise the importance of the recently commenced MRC Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial in which patients with operable gastric cancer are randomized between perioperative ECF and surgery alone. In this protocol micrometastases are treated earlier in the course of the disease than with standard adjuvant chemotherapy regimens; tumours may be downstaged and patients' nutritional status improved prior to surgery. Furthermore, according to our database, progression of locally advanced disease on ECF chemotherapy is rare (7%). This should reassure surgeons that delay will not adversely affect outcome.
Hepatobiliary tumours
Hepatobiliary tumours are rare but often present late with advanced disease not amenable to curative surgery. The results of chemotherapy in both biliary cancers and hepatoma are disappointing. 5-FU has response rates of 10%-20% in biliary cancers with response rates of 8%-31% for combination regimens reported by small trials [9] [10] [11] . Doxorubicin, the most active agent in hepatoma has response rates less than 20% with little additional benefit from combination chemotherapy [12] . We have previously reported a 40% response rate with ECF in biliary tumours and 29% in hepatomas. The regimen was well tolerated with minimal toxicity [13] . Forty-four patients have now been treated with ECF for biliary tumours with a one-year survival of 42% (unpublished data).
Pancreatic cancer
Pancreatic adenocarcinoma is the fifth most common cause of cancer death in Europe and North America affecting 12 per 100,000 of the population. At diagnosis less than 15% of patients have potentially resectable disease with fewer than 4% of patients being cured. Chemotherapy with 5-FU, adriamycin and mitomycin-C prolongs survival compared to supportive care in irresectable pancreatic cancer [14] . The combination of PVI 5-FU 300 mg/m 2 /day and cisplatin 60 mg/m 2 every three weeks has been evaluated in advanced pancreatic cancer [15] . The objective response rate was 16% (2/63 complete responses). One-year survival was 33% and this increased to 52% in patients who had local disease only. The majority of patients had improvement in symptoms and performance status improved in 34%. Chemotherapy was well tolerated with minimal grade 3/4 toxicity. These results compared favourably with other reported series including PVI 5-FU and weekly cisplatin [16] .
Colorectal cancer
Colorectal cancer is the fourth most common malignancy globally with 137,000 new cases per annum in Europe. Approximately 50% of patients will ultimately die of locally advanced or metastatic disease. Following the demonstration of increased survival and improved quality of life from palliative chemotherapy, efforts have focused on determining the optimal regimen. The toxicity observed with folinic acid modulated bolus 5-FU regimens may be reduced by administering 5-FU as short [2] or long infusions [3] . The RMH GI unit has used the short infusional 'De Gramont' regimen (LV5FU2) and PVI 5-FU, which have previously been described [2, 17] .
One hundred fifty-five patients were treated with PVI 5-FU in a randomized trial to evaluate the addition of interferon-a (IFN). IFN did not enhance the palliative benefits of PVI 5-FU but did result in significantly increased neutropenia (13% vs. 4%; P = 0.04), mucositis (61% vs. 39%; P = 0.008) and alopecia (69% vs. 21%; P = 0.0002) [13] . PVI 5-FU was well tolerated with no grade 3/4 neutropenia and a low incidence of grade 3/4 nonhaematological toxicity: 3% mucositis, 10% plantar-palmar erythema and 11% diarrhoea. The overall response rate was 28% (4 complete responses) with 40% response rate in liver metastases [17] . This cohort of patients has been compared with a similar cohort treated with a bolus 5-FU regimen, the Wadler schedule, in a second randomised trial evaluating the addition of IFN [18] . This non-randomised comparison has shown failurefree survival (P < 0.005) and overall survival (one-year survival 45.5% vs. 34.5%; P < 0.005) are significantly better for patients treated with PVI 5-FU (Figure 1 ) (unpublished data).
Thirty-four patients were treated at The Royal Marsden Hospital with LV5FU2 in a MRC randomised study comparing this regimen with or without IFN [19] . Seventeen (50%) of the patients entered at RMH were treated with the addition of interferon to LV5FU2. Nine (33%) of 33 evaluable patients achieved a response (one complete response) with an overall one-year survival of 49% (unpublished data) (Figure 1 ). Toxicity was generally mild with 6% grade 3/4 neutropenia, 10% grade 3/4 diarrhoea and 7% grade 3/4 stomatitis. The incidence of alopecia and neutropenia was increased in patients treated with IFN. The response rate and toxicity profile we achieved with LV5FU2 are similar to those reported for a randomised study of 437 patients comparing LV5FU2 with 5-FU and low-dose folinic acid according to the Mayo schedule [20] . The ambulatory chemotherapy programme has now been extended to evaluate PVI 5-FU as adjuvant chemotherapy for colorectal cancer. In this randomized study patients are treated with either 12 weeks PVI 5-FU or 5-FU 425 mg/m 2 i.v. bolus days 1-5 and folinic acid 20 mg/m 2 i.v. bolus every 28 days for six cycles. In the preliminary unpublished interim analysis including 200 patients there were significant reductions in CTC grade 3/4 neutropenia (P < 0.00001), stomatitis (P < 0.0001) and diarrhoea (P = 0.0001) with PVI 5-FU (Table 1) . This improved toxicity profile produced a reduction in time in hospital for the management of toxicity (P < 0.0001) although total inpatient time was similar for the two regimens. It is too early to report suvival and accrual continues to increase the power of the study.
Hickman lines
The ambulatory chemotherapy programme has resulted in a series of 832 patients having tunnelled central venous catheters inserted. Clinically significant complications on insertion were rare. All patients receive prophylactic antibiotics prior to insertion and warfarin 1 mg daily commencing on the day of insertion. Eighteen percent of catheters were removed because of complications including thrombosis (4.7%), infection (5.7%), migration (3.6%), pain (2.5%) and damage (2.0%). Complications requiring removal were significantly more frequent in those catheters with their tips in the superior vena cave than those in the right atrium (P -0.003). A further 15% developed complications not requiring removal, the majority of which were infections treated with antibiotics. The frequency of complications did not vary according to disease site. Quality of life issues were significantly affected in 10%-23% of patients.
Health economics
Prospectively collected hospital based costs are equivalent for ECF and FAMTX whilst PVI 5-FU is less expensive than FA-modulated 5-FU in the adjuvant colorectal cancer trial (unpublished data). An evaluation comparing the hospital-based costs of PVI 5-FU, LV5FU2 and FA-modulated 5-FU has revealed a wide variation in the pattern of costs between regimens. Total monthly costs were lowest in patients treated with the FA-modulated 5-FU, followed by PVI 5-FU and highest for LV5FU2 (Table 2 ) [21] . This demonstrates that although it is perceived that PVI chemotherapy is expensive, the benefits gained with fewer admissions and outpatient visits and less toxicity outweigh the disadvantages of catheters, pumps and support staff.
Future options
The results of our studies in the use of infusional 5-FU in the management of gastrointestinal malignancies have demonstrated high activity with low toxicity as previously observed (Table 3) . The increased response rate may be due to the higher total dose and greater dose intensity of 5-FU achieved with PVI 5-FU compared to bolus regimens. This may be particularly important in adjuvant therapy where the relationship between dose intensity and survival has been demonstrated in breast cancer [22] . The differences in mechanism of action between protracted venous infusion and bolus 5-FU may also contribute to the differences in response rate.
In vitro experiments demonstrated that the mechanism of cytotoxicity by 5-FU depends upon the dose and schedule; prolonged exposure to low doses is cytotoxic via thymidylate synthase inhibition whilst short-term exposure to high doses has a prominent effect on RNA [23] . In advanced disease the aim to increase efficacy whilst maintaining acceptable toxicity continues. Following the observation of activity with the combination of mitomycin-C and PVI 5-FU we shall be evaluating this combination in a randomised trial stratified by disease site. Further options include the evaluation of chronomodulated infusions. There is some evidence that cancer cells have abnormal circadian rhythms and in a randomised trial chronomodulated 5-FU together with FA and oxaliplatin achieved a higher dose intensity and survival advantage with less toxicity than patients received with fixed rate 5-FU [24] . The use of chronomodulated regimens may further reduce the minimal impact of ambulatory chemotherapy on quality of life. In addition, our experience is that ambulatory chemotherapy is cost-effective and further development of ambulatory chemotherapy services is justifiable.
